Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study
IntroductionGlobal phase III clinical trials have shown superior hypoglycemic efficacy to insulin and other oral hypoglycemic agents. However, there is a scarcity of real-world data comparing different glucagon-like peptide 1 receptor agonist (GLP-1RA) directly. This study aimed to assess the safety...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-03-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1347684/full |
| _version_ | 1797268760146477056 |
|---|---|
| author | Yan Jiang Han-Sheng Bai Guo-Xin Liu Shi-Yi Wang Li Yin Zhao-Ting Hou Chen-Yang Zhao Guang-Jun Fan |
| author_facet | Yan Jiang Han-Sheng Bai Guo-Xin Liu Shi-Yi Wang Li Yin Zhao-Ting Hou Chen-Yang Zhao Guang-Jun Fan |
| author_sort | Yan Jiang |
| collection | DOAJ |
| description | IntroductionGlobal phase III clinical trials have shown superior hypoglycemic efficacy to insulin and other oral hypoglycemic agents. However, there is a scarcity of real-world data comparing different glucagon-like peptide 1 receptor agonist (GLP-1RA) directly. This study aimed to assess the safety and effectiveness of various GLP-1RA in treating type 2 diabetes mellitus (T2DM) in a real-world clinical setting and identify predictive factors for favorable treatment outcomes.MethodsThis was a retrospective, single-center, real-world study. The changes in HbA1c, fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and the percentage of participants who achieved HbA1c of <7%, 7%-8%, and ≥ 8% after GLP-1RA treatment was analyzed. The clinical factors that affect the effectiveness of GLP-1RA were analyzed.ResultsAt baseline, the 249 participants had a mean baseline HbA1c of 8.7 ± 1.1%. After at least three months of follow-up, the change in HbA1c was -0.89 ± 1.3% from baseline. Dulaglutide exerted a more significant hypoglycemic effect than immediate-release exenatide. The percentage of participants who achieved HbA1c<7% was substantial, from 6.0% at baseline to 28.9%. Average body weight decreased by 2.02 ± 3.8 kg compared to baseline. After GLP-1RA treatment, the reduction in SBP was 2.4 ± 7.1 mmHg from baseline. A shorter duration of diabetes and a higher baseline HbA1c level were more likely to achieve a good response in blood glucose reduction.ConclusionsThis study provided real-world evidence showing that GLP-1RA significantly improved HbA1c, body weight, and SBP. The results can inform the decision-making about GLP-1RA treatment in daily clinical practice. |
| first_indexed | 2024-04-25T01:37:36Z |
| format | Article |
| id | doaj.art-51111edb43f24fe79449861f67a34d82 |
| institution | Directory Open Access Journal |
| issn | 1664-2392 |
| language | English |
| last_indexed | 2024-04-25T01:37:36Z |
| publishDate | 2024-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj.art-51111edb43f24fe79449861f67a34d822024-03-08T08:46:48ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-03-011510.3389/fendo.2024.13476841347684Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world studyYan JiangHan-Sheng BaiGuo-Xin LiuShi-Yi WangLi YinZhao-Ting HouChen-Yang ZhaoGuang-Jun FanIntroductionGlobal phase III clinical trials have shown superior hypoglycemic efficacy to insulin and other oral hypoglycemic agents. However, there is a scarcity of real-world data comparing different glucagon-like peptide 1 receptor agonist (GLP-1RA) directly. This study aimed to assess the safety and effectiveness of various GLP-1RA in treating type 2 diabetes mellitus (T2DM) in a real-world clinical setting and identify predictive factors for favorable treatment outcomes.MethodsThis was a retrospective, single-center, real-world study. The changes in HbA1c, fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP), diastolic blood pressure (DBP), and the percentage of participants who achieved HbA1c of <7%, 7%-8%, and ≥ 8% after GLP-1RA treatment was analyzed. The clinical factors that affect the effectiveness of GLP-1RA were analyzed.ResultsAt baseline, the 249 participants had a mean baseline HbA1c of 8.7 ± 1.1%. After at least three months of follow-up, the change in HbA1c was -0.89 ± 1.3% from baseline. Dulaglutide exerted a more significant hypoglycemic effect than immediate-release exenatide. The percentage of participants who achieved HbA1c<7% was substantial, from 6.0% at baseline to 28.9%. Average body weight decreased by 2.02 ± 3.8 kg compared to baseline. After GLP-1RA treatment, the reduction in SBP was 2.4 ± 7.1 mmHg from baseline. A shorter duration of diabetes and a higher baseline HbA1c level were more likely to achieve a good response in blood glucose reduction.ConclusionsThis study provided real-world evidence showing that GLP-1RA significantly improved HbA1c, body weight, and SBP. The results can inform the decision-making about GLP-1RA treatment in daily clinical practice.https://www.frontiersin.org/articles/10.3389/fendo.2024.1347684/fullGLP-1RAreal-world evidencetype 2 diabetes mellituseffectivenesssafety |
| spellingShingle | Yan Jiang Han-Sheng Bai Guo-Xin Liu Shi-Yi Wang Li Yin Zhao-Ting Hou Chen-Yang Zhao Guang-Jun Fan Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study Frontiers in Endocrinology GLP-1RA real-world evidence type 2 diabetes mellitus effectiveness safety |
| title | Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study |
| title_full | Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study |
| title_fullStr | Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study |
| title_full_unstemmed | Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study |
| title_short | Effectiveness and safety of glucagon-like peptide 1 receptor agonists in patients with type 2 diabetes: evidence from a retrospective real-world study |
| title_sort | effectiveness and safety of glucagon like peptide 1 receptor agonists in patients with type 2 diabetes evidence from a retrospective real world study |
| topic | GLP-1RA real-world evidence type 2 diabetes mellitus effectiveness safety |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1347684/full |
| work_keys_str_mv | AT yanjiang effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT hanshengbai effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT guoxinliu effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT shiyiwang effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT liyin effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT zhaotinghou effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT chenyangzhao effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy AT guangjunfan effectivenessandsafetyofglucagonlikepeptide1receptoragonistsinpatientswithtype2diabetesevidencefromaretrospectiverealworldstudy |